Table of Contents
Executive Summary — 5
SWOT
Analysis — 6
Table: Oman Pharmaceuticals And Healthcare
Industry SWOT — 6
Oman Political
SWOT — 7
Oman Economic SWOT — 7
Oman
Business Environment SWOT — 8
Pharmaceutical Business
Environment Ratings — 9
Table: Middle East And Africa
(MEA) – Regional Pharmaceutical Business Environment Ratings for
Q409 — 9
Limits Of Potential
Returns — 10
Risks To Realisation Of
Returns — 10
Oman - Market
Summary — 12
Regulatory Regime — 14
Recent Regulatory Developments — 15
Intellectual Property
Regime — 16
Table: Current IP Laws In
Oman — 16
Pricing And
Reimbursement — 16
Regional Price
Harmonisation — 17
Free Trade
Agreements — 18
Industry
Developments — 19
Epidemiology — 19
Table: Oman Mortality Indicators, 2006 — 20
Healthcare
Sector — 21
Table: Number Of Health Centres In Oman, By
Region — 21
Table: Number And Type Of Health Institutions
In Oman — 22
Private Healthcare
Sector — 23
Healthcare Funding — 25
Healthcare Reforms — 25
Table: Healthcare Reform
Targets — 26
Medical Tourism — 26
International Healthcare Collaboration — 27
International
Pharmaceutical Collaboration — 28
Table: India’s
Export Of Pharmaceutical Products To GCC Countries
(US$mn) — 29
Research And
Biotechnology — 29
Medical
Devices — 30
Industry Forecast
Scenario — 32
Overall Market
Forecasts — 32
Table: Oman – Drug Expenditure
Indicators, Historical Data and Forecasts — 33
Key Growth
Factors – Industry — 34
Table: Oman – Health
Expenditure Indicators, Historical Data and Forecasts — 35
Key Growth Factors – Macroeconomic — 36
Table: Oman
- Economic Activity, 2006-2013 — 38
Prescription Drug
Market Forecast — 39
Table: Oman – Prescription
Market Indicators, Historical Data and Forecasts (OMRmn unless otherwise
stated) — 40
Patented Market
Forecast — 41
Table: Oman – Patented Drug Market
Indicators, Historical Data and Forecasts — 41
Generic
Drug Market Forecast — 42
Table: Oman – Generics
Market Indicators, Historical Data and Forecasts — 43
OTC
Drug Market Forecast — 44
Table: Oman – OTC Market
Indicators, Historical Data and Forecasts (OMRmn unless otherwise
stated) — 45
Pharmaceutical Trade
Forecast — 46
Table: Oman – Pharmaceutical Trade
Indicators, Historical Data and Forecasts (US$mn) — 47
Other Healthcare Data Forecasts — 48
Table: Oman –
Other Healthcare Indicators, Historical Data and
Forecasts — 49
Key Risk To BMI’s
Forecasts — 50
Competitive
Landscape — 51
Pharmaceutical
Sector — 51
Table: Registered Pharmaceutical Companies And
Products — 51
Domestic Industry — 51
Foreign Industry — 52
Recent Industry
Developments — 52
Company Monitor — 53
Multinationals — 53
Novartis — 53
Johnson & Johnson — 55
Indigenous
Manufacturers — 57
Zynova/Oman Pharmaceutical Products
(OPP) — 57
National Pharmaceutical Industries
(NPI) — 60
BMI Methodology — 62
Country Snapshot: Oman Demographic Data — 62
Section 1:
Population — 62
Table: Demographic Indicators,
2005-2030 — 62
Table: Rural/Urban Breakdown,
2005-2030 — 63
Section 2: Education And
Healthcare — 63
Table: Education,
2002-2005 — 63
Table: Vital Statistics,
2005-2030 — 63
Section 3: Labour Market And Spending
Power — 64
Table: Employment Indicators,
1999-2004 — 64
Table: Consumer Expenditure, 2000-2012
(US$) — 64
How We Generate Our Pharmaceutical Industry
Forecasts — 65
Pharmaceutical Business Environment Ratings
Methodology — 66
Ratings Overview — 66
Table: Pharmaceutical Business Environment Indicators — 67
Weighting — 68
Table: Weighting Of
Components — 68
Sources — 68
| 
View Cart
